Gain Therapeutics Inc (GANX)
Gain Therapeutics Inc. is a biotechnology company listed on NASDAQ under the ticker GANX. The company focuses on discovering and developing novel small-molecule therapeutics for a range of diseases across therapeutic areas in Switzerland, Spain, the United States, and Australia. Its Magellan drug discovery platform is designed to identify allosteric binding sites and proprietary compounds that may modulate protein function by targeting the underlying biology of disease.
The company’s lead candidate is GT-02287, which is being evaluated in a Phase 1b study for Parkinson’s disease with or without a GBA1 mutation. Gain Therapeutics also maintains additional small-molecule programs in discovery, research, and preclinical development for conditions including dementia with Lewy bodies, Alzheimer’s disease, Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Founded in 2017, the company is based in Bethesda, Maryland.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GANX
|
$1.72
|
-11.7% Downside
|
Fair
|
$7.20
|
269.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
7.1x
|
85.105 M
|
67.83 M
|
0.8%
|
97.7%
|
-1.8
|
94.3%
|
